Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Best practices for bioinformatic characterization of neoantigens for clinical utility
Megan M. Richters, Huiming Xia, Katie M. Campbell, et al.
Genome Medicine (2019) Vol. 11, Iss. 1
Open Access | Times Cited: 176

Showing 1-25 of 176 citing articles:

Neoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 468
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
Daniel K. Wells, Marit M. van Buuren, Kristen K. Dang, et al.
Cell (2020) Vol. 183, Iss. 3, pp. 818-834.e13
Open Access | Times Cited: 407
Neoantigen: A New Breakthrough in Tumor Immunotherapy
Zheying Zhang, Manman Lu, Yu Qin, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 221
Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire
Sebastian P. Haen, Markus Löffler, Hans‐Georg Rammensee, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 10, pp. 595-610
Open Access | Times Cited: 172
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy
Cristina Puig-Saus, Barbara Sennino, Songming Peng, et al.
Nature (2023) Vol. 615, Iss. 7953, pp. 697-704
Open Access | Times Cited: 101
mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications
Yu‐Shiuan Wang, Monika Kumari, Guanhong Chen, et al.
Journal of Biomedical Science (2023) Vol. 30, Iss. 1
Open Access | Times Cited: 74
Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell
Lu Diao, Mi Liu
Advanced Science (2023) Vol. 10, Iss. 22
Open Access | Times Cited: 69
Adoptive cell therapy for cancer treatment
Shi Du, Jinyue Yan, Yonger Xue, et al.
Exploration (2023) Vol. 3, Iss. 4
Open Access | Times Cited: 47
Cancer Nanovaccines: Nanomaterials and Clinical Perspectives
Nimeet Desai, Vivek P. Chavda, Thakur Raghu Raj Singh, et al.
Small (2024) Vol. 20, Iss. 35
Open Access | Times Cited: 24
Tumour mutational burden: clinical utility, challenges and emerging improvements
Jan Budczies, Daniel Kazdal, Michael Menzel, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 10, pp. 725-742
Closed Access | Times Cited: 20
Advancing personalized immunotherapy for melanoma: Integrating immunoinformatics in multi-epitope vaccine development, neoantigen identification via NGS, and immune simulation evaluation
Mohammad Javad Kamali, Mohammad Salehi, Mohsen Karami Fath
Computers in Biology and Medicine (2025) Vol. 188, pp. 109885-109885
Closed Access | Times Cited: 2
Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group
Leticia De Mattos‐Arruda, Miguél Vázquez, Francesca Finotello, et al.
Annals of Oncology (2020) Vol. 31, Iss. 8, pp. 978-990
Open Access | Times Cited: 116
Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response
Elaine R. Mardis
Genome Medicine (2019) Vol. 11, Iss. 1
Open Access | Times Cited: 99
Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma
Matthew Labriola, Jason Zhu, Rajan T. Gupta, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000319-e000319
Open Access | Times Cited: 85
Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches
Ravi G. Gupta, Fenge Li, Jason Roszik, et al.
Cancer Discovery (2021) Vol. 11, Iss. 5, pp. 1024-1039
Open Access | Times Cited: 83
Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives
Xiaotong Chen, Ju Yang, Lifeng Wang, et al.
Theranostics (2020) Vol. 10, Iss. 13, pp. 6011-6023
Open Access | Times Cited: 77
Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma
Stephen C. Frederico, John C. Hancock, Emily E. S. Brettschneider, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 76
Neo-Antigen mRNA Vaccines
Arthur Esprit, Wout de Mey, Rajendra Bahadur Shahi, et al.
Vaccines (2020) Vol. 8, Iss. 4, pp. 776-776
Open Access | Times Cited: 75
Applying artificial intelligence for cancer immunotherapy
Zhijie Xu, Xiang Wang, Shuangshuang Zeng, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 11, Iss. 11, pp. 3393-3405
Open Access | Times Cited: 64
Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors
Lele Miao, Zhengchao Zhang, Zhijian Ren, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 56
Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy
Yu Cai, Rui Chen, Shenghan Gao, et al.
Frontiers in Oncology (2023) Vol. 12
Open Access | Times Cited: 38
Artificial intelligence in cancer immunotherapy: Applications in neoantigen recognition, antibody design and immunotherapy response prediction
Li Tong, Yupeng Li, Xiaoyi Zhu, et al.
Seminars in Cancer Biology (2023) Vol. 91, pp. 50-69
Closed Access | Times Cited: 26
Biomimetic Nanoparticle Based Targeted mRNA Vaccine Delivery as a Novel Therapy for Glioblastoma Multiforme
Tanvir Ahmed, Kazi Tasnuva Alam
AAPS PharmSciTech (2025) Vol. 26, Iss. 3
Closed Access | Times Cited: 1
Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting
Alexey V. Baldin, Lyudmila V. Savvateeva, Alexandr V. Bazhin, et al.
Cancers (2020) Vol. 12, Iss. 3, pp. 590-590
Open Access | Times Cited: 69
The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions
Karam Khaddour, Tanner M. Johanns, George Ansstas
Pharmaceuticals (2020) Vol. 13, Iss. 11, pp. 389-389
Open Access | Times Cited: 60
Page 1 - Next Page

Scroll to top